Show simple item record

dc.contributor.authorAlsaleh, M
dc.contributor.authorBarbera, T
dc.contributor.authorReeves, H
dc.contributor.authorCramp, Matthew
dc.contributor.authorRyder, S
dc.contributor.authorGabra, H
dc.contributor.authorNash, K
dc.contributor.authorShen, Y-L
dc.contributor.authorHolmes, E
dc.contributor.authorWilliams, R
dc.contributor.authorTaylor-Robinson, S
dc.date.accessioned2022-02-25T13:08:12Z
dc.date.issued2019-05-03
dc.identifier.issn1179-1535
dc.identifier.issn1179-1535
dc.identifier.urihttp://hdl.handle.net/10026.1/18847
dc.description.abstract

Background: Outside South-East Asia, most cases of cholangiocarcinoma (CCA) have an obscure etiology. There is often diagnostic uncertainty. Metabolomics using ultraperformance liquid chromatography mass spectrometry (UPLC-MS) offers the portent to distinguish disease-specific metabolic signatures. We aimed to define such a urinary metabolic signature in a patient cohort with sporadic CCA and investigate whether there were characteristic differences from those in patients with hepatocellular carcinoma (HCC), metastatic secondary liver cancer, pancreatic cancer and ovarian cancer (OCA). Methods: Spot urine specimens were obtained from 211 subjects in seven participating centers across the UK. Samples were collected from healthy controls and from patients with benign hepatic disease (gallstone, biliary strictures, sphincter of Oddi dysfunction and viral hepatitis) and patients with malignant conditions (HCC, pancreatic cancer, OCA and metastatic cancer in the liver). The spectral metabolite profiles were generated using a UPLC-MS detector and data were analyzed using multivariate and univariate statistical analyses. Results: The greatest class differences were seen between the metabolic profiles of disease-free controls compared to individuals with CCA with altered acylcarnitine, bile acid and purine levels. Individuals with benign strictures showed comparable urine profiles to patients with malignant bile duct lesions. The metabolic signatures of patients with bile duct tumors were distinguishable from patients with hepatocellular and ovarian tumors, but no difference was observed between CCA cases and patients with pancreatic cancer or hepatic secondary metastases. Conclusion: CCA causes subtle but detectable changes in the urine metabolic profiles. The findings point toward potential applications of metabonomics in early tumor detection. However, it is key to utilize both global and targeted metabonomics in a larger cohort for in-depth characterization of the urine metabolome in hepato-pancreato-biliary disease.

dc.format.extent47-67
dc.format.mediumElectronic-eCollection
dc.languageen
dc.language.isoen
dc.publisherDove Medical Press
dc.subjectcholangiocarcinoma
dc.subjectdiagnostic biomarkers
dc.subjectmetabolomics
dc.title<p>Characterization of the urinary metabolic profile of cholangiocarcinoma in a United Kingdom population</p>
dc.typejournal-article
dc.typeJournal Article
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/31118840
plymouth.volume11
plymouth.publication-statusPublished online
plymouth.journalHepatic Medicine: Evidence and Research
dc.identifier.doi10.2147/hmer.s193996
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/Peninsula Medical School
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/Research Groups
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
dc.publisher.placeNew Zealand
dcterms.dateAccepted2019-03-06
dc.rights.embargodate2022-2-26
dc.identifier.eissn1179-1535
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.2147/hmer.s193996
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2019-05-03
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV